DOSE INTENSE MOPP FOR PATIENTS WITH POOR PROGNOSIS HODGKIN'S DISEASE

该方案旨在治疗霍奇金病的子集， 治疗失败风险最高的患者。 从先前对晚期霍奇金病的研究中，我们发现 IIIB期、IVA期（骨髓）和巨大纵隔霍奇金淋巴瘤患者 这种疾病的反应和存活率较低。 为了提高 MOPP治疗在这组患者中的疗效， 所有药物都增加了，化疗后给予GM-CSF， 试图改善这些药物的预期严重骨髓毒性作用， 增加药物剂量。 迄今为止，6例可评价患者中有5例达到了 一个完整的答案。 诱导失败的患者此后 接受了同种异体骨髓移植， 反应 所有可评价患者均存活且无疾病 时间 该治疗未观察到非预期毒性。

This protocol was designed to treat the subset of Hodgkin's disease patients who are at highest risk for treatment failure. From the previous study of advanced Hodgkin's disease, we have identified patients with Stage IIIB, IVA (marrow) and massive mediastinal Hodgkin's disease as having lower response and survival rates. In order to improve the efficacy of MOPP therapy in this group of patients, dose-intensity of all drugs has been increased and GM-CSF is given following chemotherapy in an attempt to ameliorate the expected severe myelotoxic effects of these increased drug doses. To date, 5 of the 6 evaluable patients have achieved a complete response. The patient who was an induction failure has since undergone an allogeneic bone marrow transplant and achieved a complete response. All evaluable patients are alive and free of disease at this time. No unexpected toxicities have been observed with this treatment.